Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network

CD30, also known as tumor necrosis factor receptor 8 (TNF-R 8), was primarily called Ki-1 and is a cell surface molecule which has first been described from a group of pathologists from Kiel in 1982.1 CD30 can be targeted with the drug brentuximab-vedotin (BV), which is approved for relapsed or refractory CD30+ cutaneous T-cell lymphoma (CTCL) including primary cutaneous anaplastic large cell lymphoma and CD30+ mycosis fungoides and Sézary syndrome.

[1]  M. Bagot,et al.  Dramatic response to brentuximab vedotin in refractory nontransformed CD30– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission , 2019, The British journal of dermatology.

[2]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[3]  J. Scarisbrick,et al.  The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study , 2018, The American journal of surgical pathology.

[4]  R. Novoa,et al.  Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma. , 2017, The Journal of investigative dermatology.

[5]  C. Assaf,et al.  Mac attack: macrophages as key drivers of cutaneous T‐cell lymphoma pathogenesis , 2016, Experimental dermatology.

[6]  R. Advani,et al.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Diehl,et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.

[8]  Ellen J. Kim,et al.  Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin. , 2018, JAMA dermatology.